This study was funded by Grifols S.A (Barcelona, Spain), Fondo de Investigaciones Sanitarias (Project FIS 09/1964), CIBERNED (Database Project No. AC631), and by a research grant as part of the Rio Hortega program (Project No. FIS CM 09/00017 to L.Q.).
Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study
Article first published online: 11 SEP 2013
Copyright © 2013 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 48, Issue 6, pages 870–876, December 2013
How to Cite
Querol, L., Rojas-Garcia, R., Casasnovas, C., Sedano, M. J., Muñoz-Blanco, J. L., Alberti, M. A., Paradas, C., Sevilla, T., Pardo, J., Capablo, J. L., Sivera, R., Guerrero, A., Gutierrez-Rivas, E. and Illa, I. (2013), Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study. Muscle Nerve, 48: 870–876. doi: 10.1002/mus.23843
- Issue published online: 22 NOV 2013
- Article first published online: 11 SEP 2013
- Accepted manuscript online: 20 MAR 2013 04:22AM EST
- Manuscript Accepted: 11 MAR 2013
- Fondo de Investigaciones Sanitarias. Grant Number: Project FIS 09/1964
- CIBERNED. Grant Numbers: Database Project No. AC631, Project No. FIS CM 09/00017
Introduction: The objective of this retrospective study was to describe the short- and long-term patterns of IVIg use, safety, and response to treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: Response to therapy was defined as an improvement of ≥1 point on the modified Rankin score at short- and mid-term visits. Patient status at long term was classified as remission, stability, or non-responder. Results: Eighty-six patients were included; 60.5% responded at short term and 54.6% at mid-term. At long term, 25.6% of patients were in remission, 65.1% were stable, and 9.3% were non-responders. The only variable associated with remission was a better response during the first 6 months of follow-up. Conclusions: A significant percentage of patients did not require any additional drugs in the long term. This suggests that treatment effect or disease outcome may be stable over time, and treatment regimens should therefore be individualized to avoid overtreatment. Muscle Nerve 48: 870–876, 2013